{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:14:10Z","timestamp":1762604050434,"version":"build-2065373602"},"reference-count":51,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,3,26]],"date-time":"2017-03-26T00:00:00Z","timestamp":1490486400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["294713"],"award-info":[{"award-number":["294713"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["IN204416"],"award-info":[{"award-number":["IN204416"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Preclinical Research<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n<\/jats:table-wrap><\/jats:p><jats:p>The aim of this study was to determine the antiallodynic effect of acute administration of the \u03b2\u2010lactam antimicrobials, ceftriaxone (CFX) and clavulanic acid (CLAV), for the control of established pain on a model of neuropathic pain (NP). We also investigated the involvement of dopaminergic and opioidergic pathways as well as alterations in serum concentrations of TNF\u2010\u03b1 in the antiallodynic actions of these drugs. CFX, CLAV, or gabapentin (GAP), a reference drug, were administered i.p. twelve days after constriction of the sciatic nerve in rats. Mechanic and cold allodynia were evaluated for 3 h and alterations in serum concentration of TNF\u2010\u03b1 determined. Both CFX and CLAV had antiallodynic effects in response to mechanical and cold stimulation, similar to GAP. The antiallodynic effects of CFX and CLAV were blocked by haloperidol (HAL), a D2 receptor antagonist, and by naloxone (NLX), an opioid receptor antagonist. Additionally, serum TNF\u2010\u03b1 levels were attenuated following CFX and CLAV administration. These results suggest that acute administration of CFX and CLAV may represent a promising approach for treating the acute allodynia of NP, and that the mechanisms involved in these effects involve activation of dopaminergic and opioidergic pathways as well as modulation of TNF\u2010\u03b1 production. Drug Dev Res 78 : 105\u2013115, 2017. \u00a9 2017 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ddr.21381","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:58:02Z","timestamp":1490576282000},"page":"105-115","source":"Crossref","is-referenced-by-count":10,"title":["Antiallodynic Activity of Ceftriaxone and Clavulanic Acid in Acute Administration is Associated with Serum TNF\u2010\u03b1 Modulation and Activation of Dopaminergic and Opioidergic Systems"],"prefix":"10.1002","volume":"78","author":[{"given":"A.","family":"Ochoa\u2010Aguilar","sequence":"first","affiliation":[{"name":"Departmento de Farmacolog\u00eda Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico C.P. 04510 Delegaci\u00f3n Coyoac\u00e1n, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Sotomayor\u2010Sobrino","sequence":"additional","affiliation":[{"name":"Departmento de Farmacolog\u00eda Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico C.P. 04510 Delegaci\u00f3n Coyoac\u00e1n, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Jaimez","sequence":"additional","affiliation":[{"name":"Departmento de Farmacolog\u00eda Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico C.P. 04510 Delegaci\u00f3n Coyoac\u00e1n, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Departmento de Farmacolog\u00eda Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico C.P. 04510 Delegaci\u00f3n Coyoac\u00e1n, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Plancarte\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica del Dolor, Instituto Nacional de Cancerolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6580-2886","authenticated-orcid":false,"given":"R.","family":"Ventura\u2010Martinez","sequence":"additional","affiliation":[{"name":"Departmento de Farmacolog\u00eda Facultad de Medicina, Universidad Nacional Aut\u00f3noma de M\u00e9xico C.P. 04510 Delegaci\u00f3n Coyoac\u00e1n, Ciudad de M\u00e9xico M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.22.3.353"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.09.058"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.07.058"},{"key":"e_1_2_7_5_1","first-page":"3312","article-title":"Clavulanic acid exhibits anti\u2010inflammatory effects on carrageenan\u2010induced paw edema model of inflammation in rats","volume":"3","author":"Banani A","year":"2012","journal-title":"Ann Biol Res"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13330"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(88)90209-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(94)90023-X"},{"key":"e_1_2_7_9_1","first-page":"803","article-title":"Neuropathic pain and cytokines: current perspectives","volume":"6","author":"Clark AK","year":"2013","journal-title":"J Pain Res"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-6-75"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.051508.135531"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-013-1585-4"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12856"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0197-x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1642-11.2011"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.suppl_B.107"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115010-00004"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2010.12.063"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aat.2014.11.001"},{"key":"e_1_2_7_21_1","first-page":"315","article-title":"Antinociceptive effect of clavulanic acid and its preventive activity against development of morphine tolerance and dependence in animal models","volume":"9","author":"Hajhashemi V","year":"2014","journal-title":"Res Pharm Sci"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5215.2012.00656.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.11.014"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2009.04.013"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-015-2117-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.09.032"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.06.005"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.2.308"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn200072h"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02396-3"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.2010.21"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-04-01363.2002"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.05.005"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000139"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e328337be10"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(94)90038-8"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03180"},{"key":"e_1_2_7_39_1","first-page":"601","volume-title":"Clinical pharmacokinetics: concepts and applications","author":"Rowland M","year":"1989"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-012-9428-2"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2012.12.001"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1746-09.2009"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2008.03.002"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.09.018"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S118412"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/75.2.217"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000435833.33515.ba"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-07-02899.2003"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2014.991821"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aet123"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3051335"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:07:22Z","timestamp":1760382442000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/ddr.21381"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21381","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"type":"print","value":"0272-4391"},{"type":"electronic","value":"1098-2299"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}